Adrenoleukodystrophy unravelled

July 30, 2012
Adrenoleukodystrophy unravelled
Credit: Thinkstock

The European X-ALD project undertook an initiative to understand the mechanisms responsible for the pathogenesis of adrenoleukodystrophy (ALD). The gene therapy approach for treating ALD developed during the study brings hope to many young boys that have inherited the disease.

ALD is a progressive metabolic that occurs approximately in 1 in 17,000 newborns. It is caused by mutations in the ABCD1 gene located on the and affects the of the . Biochemically, X-linked ALD (X-ALD) is characterised by transport deficiency of very long-chain fatty acids (VLCFAs).

Accumulating evidence suggests that the ABCD1 gene codes for a protein that is probably implicated in the transport of VLCFAs into a specific intracellular organelle, called the . To this end, a model based on the yeast S. cerevisae has been developed to study the function of ALD protein.

Using this model, the EU-funded ‘X-linked Adrenoleukodystrophy (X-ALD): pathogenesis, animal models and therapy’ (X-ALD) project aimed to prove the role of ALD protein in VLCFA transport. Expression of ALD protein in genetically engineered yeast cells was capable of restoring the defective transport of VLCFAs. In vitro experiments using mammalian peroxisomes verified the yeast findings, conclusively demonstrating for the first time the function of the ALD protein.

Furthermore, project scientists developed new X-ALD mouse models which helped them identify candidates for modifier genes that could account for the phenotypic variability seen in ALD patients. The substantial progress made towards the understanding of the pathogenic mechanisms underlying the disease has aided the development of novel therapeutic approaches and the first clinical application of gene therapy in X-ALD.

The X-ALD work carried out in this project is expected to have significant implications with regards to future therapeutic treatment of X-ALD patients.

Explore further: New clinical practice guidelines on alcoholic liver disease published

Related Stories

New clinical practice guidelines on alcoholic liver disease published

April 19, 2012
EASL today announced the publication of a new clinical practice guideline (CPG) in the area of Alcoholic Liver Disease (ALD), bringing the number of CPGs published to date to eight.

Genes modify the risk of liver disease among alcoholics

December 6, 2011
It has been widely observed that only a small percentage of alcoholics develop cirrhosis of the liver, the most advanced form of alcoholic liver disease (ALD); the reason why all alcoholics do not develop such disease is ...

Recommended for you

Gene variant activity is surprisingly variable between tissues

August 21, 2017
Every gene in almost every cell of the body is present in two variants called alleles—one from the mother, the other one from the father. In most cases, both alleles are active and transcribed by the cells into RNA. However, ...

Genome analysis with near-complete privacy possible, say researchers

August 17, 2017
It is now possible to scour complete human genomes for the presence of disease-associated genes without revealing any genetic information not directly associated with the inquiry, say Stanford University researchers.

Science Says: DNA test results may not change health habits

August 17, 2017
If you learned your DNA made you more susceptible to getting a disease, wouldn't you work to stay healthy?

Genetic variants found to play key role in human immune system

August 16, 2017
It is widely recognized that people respond differently to infections. This can partially be explained by genetics, shows a new study published today in Nature Communications by an international collaboration of researchers ...

Active non-coding DNA might help pinpoint genetic risk for psychiatric disorders

August 16, 2017
Northwestern Medicine scientists have demonstrated a new method of analyzing non-coding regions of DNA in neurons, which may help to pinpoint which genetic variants are most important to the development of schizophrenia and ...

Phenotype varies for presumed pathogenic variants in KCNB1

August 16, 2017
(HealthDay)—De novo KCNB1 missense and loss-of-function variants are associated with neurodevelopmental disorders, with or without seizures, according to a study published online Aug. 14 in JAMA Neurology.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.